1. Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study
by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen, Annika Rewes, Mikael Frederiksen, Lisbeth Enggaard, Christian Bjørn Poulsen, Olav Jonas Bergmann, Dorte Balle Gillström, Robert Schou Pedersen, Linda Nielsen, Helle Højmark Eriksen, Christian Torp-Pedersen, Søren Risom Kristensen, and Marianne Tang Severinsen
BloodAdv
Volume 2(21):
November 13, 2018
© 2018 by The American Society of Hematology

2. Inger Lise Gade et al. Blood Adv 2018;2:3025-3034
© 2018 by The American Society of Hematology

3. Stacked cumulative incidences of VTE, second primary cancer, and death.
Stacked cumulative incidences of VTE, second primary cancer, and death. Exclusively contingent first events are depicted.
Inger Lise Gade et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Cumulative incidence of VTE according to patient-related factors and CLL-specific markers.
Cumulative incidence of VTE according to patient-related factors and CLL-specific markers. Shown are cumulative incidences of VTE in 4 different exposure categories; all patients are thus at risk in 1 of the 2 groups in each exposure category. CLL patients without a second primary cancer (yet) contributed to number at risk of VTE from the CLL diagnosis date (t0); death and second primary cancer were treated as competing risks. CLL patients exposed to a second primary cancer contributed to number at risk of VTE from the second primary cancer diagnosis date (t0); death was treated as a competing risk (A). Too few events among CLL patients with Binet C, when a second primary cancer was treated as a competing risk, precluded a separate graph for this group (B).
Inger Lise Gade et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Cumulative incidence of VTE in CLL depicted, treating solely death and death plus second primary cancer as competing risks.
Cumulative incidence of VTE in CLL depicted, treating solely death and death plus second primary cancer as competing risks.
Inger Lise Gade et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

6. Cumulative mortality according to diagnosis of VTE
Cumulative mortality according to diagnosis of VTE. VTE is treated as competing risk among those not (yet) exposed to VTE.
Cumulative mortality according to diagnosis of VTE. VTE is treated as competing risk among those not (yet) exposed to VTE.
Inger Lise Gade et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology